Chad Swanson, PhD, Eisai Inc., summarizes the potential of lecanemab for the treatment of early Alzheimer’s disease, based on findings from the open-label extension (OLE) of the Phase II BAN2401-G000-201 study (NCT01767311). Dr Swanson discusses in more detail how the effects of lecanemab on brain amyloid are seen as early as three months into treatment, with over 80% of subjects becoming amyloid negative as early as 12 months and reduction in amyloid in the Phase II study correlating with a slowing in clinical decline. The evidence supporting the continued use of lecanemab for patients with early AD is also summarized. Dr Swanson concludes by explaining that these OLE data are hypothesis-generating and will help guide analyses in the ongoing Phase III Clarity AD study (NCT03887455). This interview took place during the Alzheimer’s Association International Conference (AAIC), 2021.

свернуть